Skip to content
Cyclodextrin News

Cyclodextrin News

A forum for researchers, students and applicants in the field of cyclodextrin technology

  • Home
  • Pharma applications
  • Non-pharma applications
  • CD derivatives
  • Events
  • E-ducation

Tag: neurodegeneration

December 10, 2024 CD as API / Drug delivery / Pharma applications

Alzheimer’s Disease as Type 3 Diabetes: Understanding the Link and Implications

Alzheimer’s disease (AD) and type 2 diabetes mellitus (T2DM) are two prevalent conditions that present considerable public health issue in

Continue reading

September 11, 2024 Drug delivery / Pharma applications

A new therapeutic approach to neurodegeneration? An old, known drug restarts flow of brain-cleaning fluids

On 15 August, 2024 Douglas Kelley, professor of mechanical engineering at the University of Rochester and his co-workers published that

Continue reading

July 25, 2023 CD as API / Pharma applications

Long-term administration of intravenous Trappsol® Cyclo™ (HP-β-CD) in Niemann-Pick disease type C1: Results of an international 48-week Phase I/II trial

Niemann-Pick disease type C (NPC) is a rare, fatal, pan-ethnic, autosomal recessive lysosomal storage disease characterized by progressive major organ

Continue reading

February 16, 2023 Drug delivery / Pharma applications

Nanotherapeutic and Stem Cell Therapeutic Strategies in Neurodegenerative Diseases: A Promising Therapeutic Approach

Neurodegeneration is characterized by progressive, disabling, and incurable neurological disorders with the massive loss of specific neurons. As one of

Continue reading

August 26, 2021 CD as API / Pharma applications

Repeated administration of 2-hydroxypropyl-β-cyclodextrin (HPβCD) attenuates the chronic inflammatory response to experimental stroke

Globally, more than 67 million people are living with the effects of ischemic stroke. Importantly, many stroke survivors develop a

Continue reading

June 21, 2021 CD as API / Pharma applications

Mallinckrodt gave up further development of adrabetadex (VTS-270; HPBCD)

Mallinckrodt Pharmaceuticals has reached an agreement to divest and transfer the Investigational New Drug (IND) application for experimental drug adrabetadex

Continue reading

April 21, 2021 CD as API / Drug delivery / Pharma applications

Central nervous system delivery of molecules across the blood-brain barrier

Therapies targeting neurological conditions such as Alzheimer’s or Parkinson’s diseases are hampered by the presence of the blood-brain barrier (BBB).

Continue reading

February 4, 2021 CD as API / Drug delivery / Events

Press Release – Development of Autophagy Inducing Cyclodextrin Derivatives for Aging-associated Diseases

CycloLab Cyclodextrin R&D Ltd. proudly announces winning of a national grant about the development of cyclodextrin-dervatives for autophagy-associated neurodegenerative diseases.

Continue reading

May 15, 2020 CD as API / Pharma applications

Cyclo Therapeutics reports international patent application for treating Alzheimer’s

Cyclo Therapeutics reported the publication of an international patent application for the treatment of Alzheimer’s disease with HPBCD.

November 8, 2019 CD as API / Drug delivery / Pharma applications

World Congress on Neuroscience and Brain Disorders

“World Congress on Neuroscience and Brain Disorders” is scheduled to be held from March 30-31, 2020 in Osaka, Japan. The

Continue reading

Posts pagination

1 2 Next Posts»

Recent Posts

  • Special issue: “Synthesis, Analysis and Applications of Cyclodextrins and Their Derivatives”
  • Multiscale mechanistic analysis of reversible cross-linking polymers based on host–guest interactions
  • Redox responsive cyclodextrin-based drug delivery systems: a special insight to glutathione responsive CD-nanosponges
  • CD in prevention of dengue-induced lethality
  • A Bubble-Driven Drug Delivery System Enhances Oral Absorption and Antipyretic Efficacy of Poorly Water-Soluble Andrographolide

Tags

alpha-CD Alzheimer disease atherosclerosis Cancer therapy Captisol Cholesterol Clinical trial conference Covid-19 cyclodextrin polymer Dexolve drug delivery drug delivery systems electrospinning FDA Food gamma-CD Gilead HPBCD hydrogel methyl BCD Nanoparticles Niemann Pick Disease RAMEB remdesivir review SBECD Special issue Synthesis

Follow Us

  • LinkedIn
  • X
  • Facebook

Categories

  • Agriculture (26)
  • Analysis (64)
  • CD as API (341)
  • CD derivatives (400)
  • Cosmetics and toilettry (49)
  • Diagnosis (12)
  • Drug delivery (780)
  • E-ducation (63)
  • Environmental (131)
  • Events (232)
  • Food (217)
  • Gene delivery (19)
  • Household products (4)
  • Household products (1)
  • In Hungarian (4)
  • Life sciences (42)
  • Non-pharma applications (393)
  • Other industrial use (104)
  • Pharma applications (1,167)
  • Supramolecular systems (40)
  • Uncategorized (140)

Top Posts

  • Lanosterol eye drops for cataract treatment
  • Sweets for Christmas
  • Oral alpha-cyclodextrin reverses cholesterol-crystal-induced retinal pathology in a rodent model of type 2 diabetes (T2D)
  • MIT scientists filed patent for HPBCD treatment in Alzheimer's disease
  • Pilocarpine eye drops (Vuity)
  • Egg-Free Bakery - Recommendation from Wacker
  • A cyclodextrin-based turn-off fluorescent probe for naked-eye detection of copper ions in aqueous solution
  • JIC Venture Growth Investments Invests in Beren Therapeutics P.B.C. to Advance Innovative, Cyclodextrin-based Therapeutics
  • Special issue: “Synthesis, Analysis and Applications of Cyclodextrins and Their Derivatives”
  • Different cyclodextrins to treat NPC

Subscribe to Blog via Email

Enter your email address to subscribe to this blog and receive notifications of new posts by email.

Join 3,791 other subscribers
 

Loading Comments...